公开(公告)号：US12006349B2

公开(公告)日：2024-06-11

申请号：US17396323

申请日：2021-08-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Lea Stevermann

IPC: A61K38/00 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/00 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N9/64 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/566 ,  G01N33/569

CPC classification number: C07K14/70539 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12Q1/6886 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US11957742B2

公开(公告)日：2024-04-16

申请号：US18158604

申请日：2023-01-24

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K39/00 ,  A61P35/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574

CPC classification number: A61K39/0011 ,  A61P35/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2833 ,  C07K16/3076 ,  C12N5/0636 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/57492 ,  A61K39/00 ,  A61K2039/5158 ,  C07K2319/40 ,  C12N2310/16 ,  C12N2501/50 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N2333/70539

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US11951160B2

公开(公告)日：2024-04-09

申请号：US17669454

申请日：2022-02-11

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K39/00 ,  A61P35/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574

CPC classification number: A61K39/0011 ,  A61P35/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/4748 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2833 ,  C07K16/3076 ,  C12N5/0636 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/57492 ,  A61K39/00 ,  A61K2039/5158 ,  C07K2319/40 ,  C12N2310/16 ,  C12N2501/50 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N2333/70539

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US11951132B2

公开(公告)日：2024-04-09

申请号：US17377735

申请日：2021-07-16

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko Schuster ,  Franziska Hoffgaard ,  Jens Fritsche ,  Oliver Schoor ,  Toni Weinschenk ,  Daniel Johannes Kowalewski ,  Chih-Chiang Tsou

IPC: A61K39/00 ,  A61K35/17 ,  A61K38/08 ,  A61K39/12 ,  A61K39/39 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K7/06 ,  C07K14/47 ,  C07K14/54 ,  C07K16/24 ,  C07K16/28 ,  C12N5/0783 ,  A61K45/00

CPC classification number: A61K35/17 ,  A61K38/08 ,  A61K39/001102 ,  A61K39/001114 ,  A61K39/001118 ,  A61K39/12 ,  A61K39/39 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K7/06 ,  C07K14/4748 ,  C07K14/5434 ,  C07K16/244 ,  C07K16/2818 ,  C07K16/2821 ,  C12N5/0636 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/55516 ,  A61K2039/55533 ,  A61K2039/55538 ,  A61K2039/55561 ,  A61K2039/572 ,  A61K2039/585 ,  A61K45/05

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US11945850B2

公开(公告)日：2024-04-02

申请号：US16571982

申请日：2019-09-16

Applicant: Immatics Biotechnologies GmbH

Inventor： Colette Song ,  Heiko Schuster ,  Daniel Johannes Kowalewski ,  Oliver Schoor ,  Jens Fritsche ,  Toni Weinschenk ,  Harpreet Singh

IPC: C07K14/47 ,  A61K35/17 ,  A61K38/08 ,  A61K39/00 ,  C07K7/04 ,  C07K7/06 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C12N5/0783 ,  C12Q1/6886 ,  G16B25/10

CPC classification number: C07K14/4748 ,  A61K35/17 ,  A61K39/0011 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/18 ,  C12N5/0636 ,  C12Q1/6886 ,  A61K38/08 ,  C07K7/04 ,  C07K7/06 ,  C07K2319/00 ,  C07K2319/55 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G16B25/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US11938176B2

公开(公告)日：2024-03-26

申请号：US17314492

申请日：2021-05-07

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Colette Song

IPC: A61K39/00 ,  A61K35/17 ,  A61P35/00 ,  C07K14/47 ,  C07K14/74 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/115 ,  G16B25/00 ,  G16B25/10 ,  A61K35/12 ,  C07K14/705

CPC classification number: A61K39/0011 ,  A61K35/17 ,  A61K39/001102 ,  A61P35/00 ,  C07K14/4748 ,  C07K14/70539 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/3038 ,  C12N5/0636 ,  C12N15/115 ,  G16B25/00 ,  G16B25/10 ,  A61K2035/124 ,  A61K2039/505 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K14/705 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/33 ,  C07K2319/55 ,  C12N2310/16

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US11932678B2

公开(公告)日：2024-03-19

申请号：US17314650

申请日：2021-05-07

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Colette Song ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: C07K14/00 ,  A61K35/17 ,  A61K39/00 ,  C07K14/47 ,  C07K14/635 ,  C07K14/725 ,  C07K14/74 ,  C07K16/28 ,  C12N5/0783 ,  C12Q1/6886 ,  G01N33/574 ,  A61K38/00

CPC classification number: C07K14/70539 ,  A61K35/17 ,  A61K39/0011 ,  C07K14/4748 ,  C07K14/635 ,  C07K14/7051 ,  C07K16/2833 ,  C12N5/0638 ,  C12Q1/6886 ,  G01N33/57484 ,  A61K38/00 ,  A61K39/00 ,  C07K2319/70 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US11866517B2

公开(公告)日：2024-01-09

申请号：US17525023

申请日：2021-11-12

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni Weinschenk ,  Steffen Walter ,  Jens Fritsche ,  Colette Song ,  Harpreet Singh

IPC: A61K38/08 ,  C07K7/08 ,  C12N5/0783 ,  C12N9/64 ,  A61K38/17 ,  C07K7/06 ,  A61K39/00 ,  A61K45/06 ,  C07K14/725

CPC classification number: C07K7/08 ,  A61K38/1709 ,  A61K39/0011 ,  A61K45/06 ,  C07K7/06 ,  C07K14/7051 ,  C12N5/0638 ,  C12N9/6491 ,  C12Y304/24065 ,  A61K2039/5158 ,  A61K2039/572 ,  C12N2502/11

Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an WIC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.

公开(公告)号：US11859017B2

公开(公告)日：2024-01-02

申请号：US17698531

申请日：2022-03-18

Applicant: Immatics Biotechnologies GmbH

Inventor： Toni Weinschenk ,  Steffen Walter ,  Jens Fritsche ,  Colette Song ,  Harpreet Singh

IPC: A61K38/08 ,  C07K7/08 ,  C12N5/0783 ,  C12N9/64 ,  A61K38/17 ,  C07K7/06 ,  A61K39/00 ,  A61K45/06 ,  C07K14/725

CPC classification number: C07K7/08 ,  A61K38/1709 ,  A61K39/0011 ,  A61K45/06 ,  C07K7/06 ,  C07K14/7051 ,  C12N5/0638 ,  C12N9/6491 ,  C12Y304/24065 ,  A61K2039/5158 ,  A61K2039/572 ,  C12N2502/11

Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.

公开(公告)号：US11850274B2

公开(公告)日：2023-12-26

申请号：US17238943

申请日：2021-04-23

Applicant: Immatics Biotechnologies GmbH

Inventor： Jens Fritsche ,  Toni Weinschenk ,  Steffen Walter ,  Peter Lewandrowski ,  Harpreet Singh

IPC: A61P35/00 ,  C07K7/06 ,  A61K38/17 ,  A61K39/00 ,  G01N33/50

CPC classification number: A61K38/1709 ,  A61K39/0011 ,  A61P35/00 ,  C07K7/06 ,  G01N33/505 ,  A61K2039/5158 ,  A61K2039/572 ,  A61K2039/585 ,  C07K2319/00

Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a WIC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.